Literature DB >> 27757817

Novel Treatments for Cyclic Vomiting Syndrome: Beyond Ondansetron and Amitriptyline.

Sanjay Bhandari1, Thangam Venkatesan2.   

Abstract

OPINION STATEMENT: Cyclic vomiting syndrome (CVS) is a chronic functional gastrointestinal disorder that is characterized by episodic nausea and vomiting. Initially thought to only affect children, CVS in adults was often misdiagnosed with significant delays in therapy. Over the last decade, there has been a considerable increase in recognition of CVS in adults but there continues to be a lack of knowledge about management of this disorder. This paper seeks to provide best practices in the treatment of CVS and also highlight some novel therapies that have the potential in better treating this disorder in the future. Due to the absence of randomized control trials, we provide recommendations based on review of the available literature and expert consensus on the therapy of CVS. This paper will discuss prophylactic and abortive therapy and general measures used to treat an episode of CVS and also discuss pathophysiology as it pertains to novel therapy. Recent recognition of the association of chronic marijuana use with cyclic vomiting has led to the possibility of a new diagnosis called "Cannabinoid Hyperemesis Syndrome," which is indistinguishable from CVS. The treatment for this purported condition is abstinence from marijuana despite scant evidence that marijuana use is causative. Hence, this review will also discuss emerging data on the role for the endocannabinoid system in CVS and therapeutic agents targeting the endocannabinoid system, which offer the potential of transforming the care of these patients.

Entities:  

Keywords:  Biopsychosocial; CB1 receptor agonist; Cyclic vomiting syndrome; FAAH inhibitors; NK1 receptor antagonists; Tricyclic antidepressants

Year:  2016        PMID: 27757817     DOI: 10.1007/s11938-016-0114-y

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  44 in total

1.  Cannabinoid hyperemesis: a case series of 98 patients.

Authors:  Douglas A Simonetto; Amy S Oxentenko; Margot L Herman; Jason H Szostek
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

2.  Spectrum of gastric emptying patterns in adult patients with cyclic vomiting syndrome.

Authors:  R A Hejazi; T H Lavenbarg; R W McCallum
Journal:  Neurogastroenterol Motil       Date:  2010-08-19       Impact factor: 3.598

3.  The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.

Authors:  Nissar A Darmani
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

4.  Darwin's illness revisited.

Authors:  John A Hayman
Journal:  BMJ       Date:  2009-12-10

5.  Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells.

Authors:  T Sugiura; T Kodaka; S Kondo; S Nakane; H Kondo; K Waku; Y Ishima; K Watanabe; I Yamamoto
Journal:  J Biochem       Date:  1997-10       Impact factor: 3.387

6.  L-carnitine administration reduces number of episodes in cyclic vomiting syndrome.

Authors:  Sandra C Van Calcar; Cary O Harding; Jon A Wolff
Journal:  Clin Pediatr (Phila)       Date:  2002-04       Impact factor: 1.168

7.  Zonisamide or levetiracetam for adults with cyclic vomiting syndrome: a case series.

Authors:  Ray E Clouse; Gregory S Sayuk; Patrick J Lustman; Chandra Prakash
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12-06       Impact factor: 11.382

8.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

9.  Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.

Authors:  J H Allen; G M de Moore; R Heddle; J C Twartz
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

Review 10.  Cyclic vomiting syndrome in adults.

Authors:  T L Abell; K A Adams; R G Boles; A Bousvaros; S K F Chong; D R Fleisher; W L Hasler; P E Hyman; R M Issenman; B U K Li; S L Linder; E A Mayer; R W McCallum; K Olden; H P Parkman; C D Rudolph; Y Taché; S Tarbell; N Vakil
Journal:  Neurogastroenterol Motil       Date:  2008-04       Impact factor: 3.598

View more
  7 in total

1.  Intravenous haloperidol for the treatment of intractable vomiting, cyclical vomiting, and gastroparesis.

Authors:  Brad E Schwartz; Karen Keller Baker; Andrew J Bleinberger; Amina Lleshi; Raul Cruz-Cano
Journal:  World J Emerg Med       Date:  2021

Review 2.  Cyclic Vomiting Syndrome in Children and Adults: What Is New in 2018?

Authors:  Katja Kovacic; Manu Sood; Thangam Venkatesan
Journal:  Curr Gastroenterol Rep       Date:  2018-08-29

Review 3.  Cyclic vomiting syndrome: epidemiology, diagnosis, and treatment.

Authors:  Sanjay Bhandari; Pinky Jha; Abhishek Thakur; Abhipsa Kar; Harrison Gerdes; Thangam Venkatesan
Journal:  Clin Auton Res       Date:  2018-02-13       Impact factor: 4.435

4.  Cyclic Vomiting Syndrome in Pediatric Patients: A Review of Therapeutics.

Authors:  Emma M Tillman; Emily M Harvath
Journal:  J Pediatr Pharmacol Ther       Date:  2021-12-22

Review 5.  Migraine, Cyclic Vomiting Syndrome, and Other Gastrointestinal Disorders.

Authors:  Elliot S Yu; Yasodara Priyadharsini S S; Thangam Venkatesan
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

6.  Highlighting the importance of early diagnosis of cyclic vomiting syndrome in adults: A case report.

Authors:  Cuilan Tang; Ning Dai
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

7.  Differential Diagnosis of Cyclic Vomiting and Periodic Headaches in a Child with Ventriculoperitoneal Shunt: Case Report of Chronic Shunt Overdrainage.

Authors:  Maximilian David Mauritz; Carola Hasan; Lutz Schreiber; Andreas Wegener-Panzer; Sylvia Barth; Boris Zernikow
Journal:  Children (Basel)       Date:  2022-03-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.